Since NF-κB is a dominant oncogene in NSCLC and plays an important role in glucose metabolism homeostasis, manipulating the interaction between NF-κB and OVOL2 may constitute a new therapeutic approach for lung cancer. This evidence concerns the gene OVOL2 and non-small cell lung carcinoma.